HL GENOMICS Co., Ltd.

As of June 30, 2026, HL GENOMICS Co., Ltd. has 7.76M shares outstanding.

As of June 30, 2026, HL GENOMICS Co., Ltd. maintains a current ratio of 16.21, meaning it holds 16.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 118.00M in revenue per employee across its workforce of 56.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, HL GENOMICS Co., Ltd. recorded 655.76M in income tax expense. That works out to an effective tax rate of 26.84, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

These figures are as of the close on October 23, 2026.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, HL GENOMICS Co., Ltd. holds 40.93B in cash and equivalents against 3.44B in total debt, resulting in a net debt position of -4.93B. Total book value stands at 87.99B, with working capital of 50.53B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -172.38M in capital expenditures, free cash flow totaled 2.36B - equivalent to 392.66 per share.

Over the twelve months ended June 30, 2026, HL GENOMICS Co., Ltd. posted a gross margin of 44.75, reflecting its pricing power and cost economics. The operating margin of 32.03 and net profit margin of 27.05 provide insight into operational efficiency.